Nasdaq GlobeNewswire

Kraig Biocraft Laboratories Creates First Hybrids in New Research Center

ANN ARBOR, Mich., Jan. 19, 2018 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that the Company succeeded in creating a new hybrid transgenic silkworm at its Michigan production facility.  This is the first hybrid silkworm created at the new Michigan facility, which recently opened in October of 2017. 

Phase 1b/2 Study of Margetuximab in Combination with Pembrolizumab Presented at 2018 ASCO Gastrointestinal Cancers Symposium

  • Chemotherapy-free, immunotherapeutic combination evaluated
  • 32% Overall response rate in second-line gastric cancer patients
  • Well tolerated in dose escalation and expansion cohorts

EVIO Inc. Announces 438% Revenue Growth for the Fiscal Year Ended September 30, 2017

BEND, Ore., Jan. 18, 2018 (GLOBE NEWSWIRE) -- EVIO, Inc. (OTCQB:EVIO), a leading provider of quality control testing and advisory services to the regulated cannabis industry, announces financial and operating results for the fiscal year ended September 30, 2017.

Cannabis Science Announces an Overwhelming Response to its Groundbreaking Research on the Use of Cannabinoids in the Treatment of Cancers, Already Has More Views Than 91% of the Papers Published in all Frontiers Journals

 

IRVINE, CA, Jan. 18, 2018 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to report very strong interest among researchers in the Company’s groundbreaking work to investigate the use of cannabinoids in the treatment of cancers. Cannabis Science’s recent, peer-reviewed publication in Frontiers in Oncology, “Nanoparticle Drones to Target Lung Cancer with Radiosensitizers and Cannabinoids”, in just a few months, has already been viewed more than 6,500 times, with the article having more views than 91% of the papers published in all Frontiers journals.

Organovo Announces Release Date for Fiscal Third-Quarter 2018 Financial Results

 

SAN DIEGO, Jan. 18, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) will host a conference call on Thursday, February 8, 2018 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fiscal third-quarter 2018 financial results.  In advance of the call on February 8, 2018, Organovo will issue its fiscal third-quarter 2018 earnings press release, which will be available at http://www.organovo.com.  To participate in the teleconference, callers can dial the following numbers:

Biorasi Opens Japan Office

 

Miami, FL, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Biorasi, a leading full-service global CRO, is pleased to announce today the opening of their new Japanese office, located in Tokyo. This milestone marks Biorasi’s first regional headquarters located in East Asia, and dramatically expands Biorasi’s capabilities to manage trials in Japan and surrounding territories. The new office will become the command center for all East-Asian operations.

Predictive Technology Group Appoints Dr. Gregory A. Prince to Its Scientific Advisory Board

SALT LAKE CITY, Jan. 17, 2018 (GLOBE NEWSWIRE) --

Innovative Humanized Research Strategies for Immuno-Oncology Drug Development, Crown Bioscience Hosts a Live Webinar

 

SAN DIEGO, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, will host a webinar on Thursday, January 18, 2018 at 10 am EST (3pm BST/UK), presented by renowned immunologist, Dr. Jayant Thatte. Dr. Thatte will review currently available humanized models and describe innovative applications for preclinical immuno-oncology research.

Strongbridge Biopharma plc Announces Acquisition of the U.S. and Canadian Rights to MACRILEN™ (macimorelin) from Aeterna Zentaris

~ MACRILEN is the First and Only FDA-Approved Oral Drug Indicated For the Diagnosis of Adult Growth Hormone Deficiency, a Rare Endocrine Disorder ~

Pivot Continues To Build Technology Portfolio

 

VANCOUVER, British Columbia, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Pivot Pharmaceuticals Inc. (CSE:PVOT) (OTCQB:PVOTF) (“Pivot” or the “Company”), and its wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), are pleased to provide its shareholders with a Corporate Update.

CORRECTION -- Arzeda Strengthens Board of Directors with Addition of Biotechnology Veteran William Baum

SEATTLE, Jan. 16, 2018 (GLOBE NEWSWIRE) -- In a release issued under the same headline on December 21, 2017 by Arzeda, we are advised by the company that "OP Fund" in the second paragraph should have read "OS Fund." The corrected release follows:

SV Health Investors Announces Promotions Within Financial Team

 

BOSTON, Jan. 16, 2018 (GLOBE NEWSWIRE) -- SV Health Investors, the venture capital and growth equity firm, has promoted Denise Marks to Chief Administrative Partner from Chief Financial Officer and Brent Faduski to Chief Financial Officer from Controller.

Taglich Brothers Initiates Nexeon Medsystems Inc.

 

NEW YORK, Jan. 16, 2018 (GLOBE NEWSWIRE) -- Taglich Brothers, Inc. announces that it has initiated coverage of Nexeon Medsystems Inc. (OTC:NXNN).

Arbutus Announces Closing of the Second Tranche of a $116M Strategic Investment from Roivant Sciences

 

VANCOUVER, British Columbia and WARMINSTER, Pa., Jan. 16, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, today announced the closing of the issue and sale of 664,000 series A participating convertible preferred shares of Arbutus (Preferred Shares) to Roivant Sciences Ltd. (Roivant) for gross proceeds to Arbutus of US$66.4 million (Tranche 2). Tranche 2 closed on January 12, 2018 following receipt of the approval of Arbutus’ shareholders on January 11, 2018. The Tranche 2 closing represents the second of two tranches of Preferred Shares issued to Roivant and, together with the previously announced Tranche 1 closing, comprise the previously announced US$116.4 million strategic investment by Roivant in Arbutus.

PetMed Express D/B/A 1-800-PetMeds to Announce Its Third Quarter Financial Results on January 22, 2018

DELRAY BEACH, Fla., Jan. 16, 2018 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (NASDAQ:PETS) will announce its financial results for the quarter ended December 31, 2017 on Monday, January 22, 2018 at 8:00 A.M. Eastern Time, then at 8:30 A.M. Eastern Time, Menderes Akdag, the Company’s Chief Executive Officer and President, will host a conference call to review the financial results.

Capricor Announces Licensing of Additional Patent Applications from Cedars-Sinai Medical Center for Cellular and Exosome-based Technologies

 

LOS ANGELES, Jan. 16, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR)  announced today that it has added seven new patent applications to its existing Exclusive License Agreements with Cedars-Sinai Medical Center for technologies related to cardiosphere-derived cells (CDCs) and CDC-derived extracellular vesicles, including exosomes.

Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Metastatic Breast Cancer

 

SALT LAKE CITY, Jan. 12, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug Administration (FDA) approved BRACAnalysis CDx® for use as a companion diagnostic by healthcare professionals to identify patients with HER2-negative metastatic breast cancer who have a germline BRCA mutation and are candidates for treatment with the PARP inhibitor Lynparza (olaparib), marketed by AstraZeneca and Merck, known as MSD outside of the U.S. and Canada.  BRACAnalysis CDx is the first and only FDA-approved test for use in this indication.

Devonian annonce les résultats de l’assemblée générale annuelle et extraordinaire des actionnaires

 

QUEBEC, 12 janv. 2018 (GLOBE NEWSWIRE) -- Groupe Santé Devonian Inc. (« Devonian » ou la « Société ») (TSX CROISSANCE:GSD) une société pharmaceutique botanique au stade de développement clinique, a annoncé aujourd'hui les résultats du vote de son assemblée générale annuelle et extraordinaire tenue le 11 janvier 2018 à Québec (Québec). Le nombre d'actions représentées en personne ou par procuration représentait 81,30% du total des actions émises et en circulation de Devonian.

Devonian Announces voting results of the Annual General and Special Meeting

QUEBEC CITY, Jan. 12, 2018 (GLOBE NEWSWIRE) -- Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSX VENTURE:GSD), a clinical stage botanical pharmaceutical corporation, today announces the voting results of its Annual General and Special Meeting held on January 11, 2018 in Quebec City, Quebec.  The number of shares represented in person or by proxy represented 81.30 % of the total issued and outstanding Devonian’s shares. 

AquaBounty Technologies, Inc. Announces $12 Million Underwritten Public Offering

 

MAYNARD, Mass., Jan. 12, 2018 (GLOBE NEWSWIRE) -- AquaBounty Technologies, Inc. (Nasdaq:AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (NYSE:XON), today announced that it has priced an underwritten public offering of an aggregate of 3,692,307 shares of common stock of the Company, together with warrants to purchase up to 3,692,307 shares of common stock of the Company, at an offering price of $3.25 per share and associated warrant. In addition, AquaBounty has granted the underwriter a 30-day option to purchase up to 553,846 additional shares of common stock and/or additional warrants to purchase up to 553,846 shares of common stock, at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about January 17, 2018, subject to satisfaction of customary closing conditions.